文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

脓毒性休克患者可溶性髓系细胞触发受体1持续升高及单核细胞人类白细胞抗原DR表达降低与院内感染相关

Persistently Elevated Soluble Triggering Receptor Expressed on Myeloid Cells 1 and Decreased Monocyte Human Leucocyte Antigen DR Expression Are Associated With Nosocomial Infections in Septic Shock Patients.
PubMed 文献 · Crit Care Explor · 2023-02-24
一句话结论脓毒性休克患者D6/D8时sTREM-1持续升高且mHLA-DR降低者院内感染风险显著增高(60% vs 15.7%),作者认为两者联合可能有助于识别免疫抑制高危患者。

该研究为法国大学医院开展的观察性研究,系IMMUNOSEPSIS队列(NCT04067674)的事后分析,纳入116例成人脓毒性休克患者,于入ICU后D1/D2、D3/D4、D6/D8检测血浆sTREM-1与单核细胞HLA-DR。多因素分析显示,D6/D8时mHLA-DR降低与继发感染风险增加独立相关(亚分布风险比3.61,95%CI 1.39-9.34,p=0.008);D6/D8时sTREM-1持续升高且mHLA-DR降低者感染发生率为60%,其他患者为15.7%,多因素模型中亚分布风险比4.65(95%CI 1.98-10.9,p<0.001)。作者认为sTREM-1联合mHLA-DR可能有助于识别院内感染高危的免疫抑制患者。

要点

  • D6/D8时mHLA-DR降低与继发感染风险增加独立相关,亚分布风险比3.61(95%CI 1.39-9.34,p=0.008)。
  • D6/D8时sTREM-1持续升高且mHLA-DR降低者感染发生率为60%,其他患者为15.7%。
  • 上述联合标志物与感染风险的关联在多因素模型中仍显著,亚分布风险比4.65(95%CI 1.98-10.9,p<0.001)。
  • 非存活者各时间点mHLA-DR均显著低于存活者,sTREM-1浓度均高于存活者。
  • 作者认为sTREM-1联合mHLA-DR可能有助于识别院内感染高危的免疫抑制患者。

适用人群与场景

  • 法国大学医院成人脓毒性休克患者,共116例,为IMMUNOSEPSIS队列(NCT04067674)的事后研究。

研究设计与关键结果

  • 研究类型为观察性研究,系IMMUNOSEPSIS队列(NCT04067674)的事后分析,纳入116例成人脓毒性休克患者,无干预。
  • 于入ICU后D1/D2、D3/D4、D6/D8检测血浆sTREM-1与单核细胞HLA-DR,通过多因素分析评估与院内感染的关联;D6/D8时联合两标志物,在标志物最失调亚组中以死亡为竞争风险行多因素分析。
  • 非存活者较存活者各时间点mHLA-DR显著降低、sTREM-1浓度升高。
  • D6/D8时mHLA-DR降低与继发感染风险增加独立相关,校正临床参数后亚分布风险比3.61(95%CI 1.39-9.34,p=0.008)。
  • D6/D8时sTREM-1持续升高且mHLA-DR降低者感染发生率为60%,其他患者为15.7%;多因素模型中亚分布风险比4.65(95%CI 1.98-10.9,p<0.001)。

证据类型、等级与局限

  • 证据类型:观察性研究(IMMUNOSEPSIS队列的事后分析)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为sTREM-1联合mHLA-DR可能有助于更好地识别院内感染高危的免疫抑制患者。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

UNLABELLED: Sepsis-acquired immunosuppression may play a major role in patients' prognosis through increased risk of secondary infections. Triggering receptor expressed on myeloid cells 1 (TREM-1) is an innate immune receptor involved in cellular activation. Its soluble form (sTREM-1) has been described as a robust marker of mortality in sepsis. The objective of this study was to evaluate its association with the occurrence of nosocomial infections alone or in combination with human leucocyte antigen-DR on monocytes (mHLA-DR).

DESIGN: Observational study.

SETTING: University Hospital in France.

PATIENTS: One hundred sixteen adult septic shock patients as a post hoc study from the IMMUNOSEPSIS cohort (NCT04067674).

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Plasma sTREM-1 and monocyte HLA-DR were measured at day 1 or 2 (D1/D2), D3/D4, and D6/D8 after admission. Associations with nosocomial infection were evaluated through multivariable analyses. At D6/D8, both markers were combined, and association with increased risk of nosocomial infection was evaluated in the subgroup of patients with most deregulated markers in a multivariable analysis with death as a competing risk. Significantly decreased mHLA-DR at D6/D8 and increased sTREM-1 concentrations were measured at all time points in nonsurvivors compared with survivors. Decreased mHLA-DR at D6/D8 was significantly associated with increased risk of secondary infections after adjustment for clinical parameters with a subdistribution hazard ratio of 3.61 (95% CI, 1.39-9.34; p = 0.008). At D6/D8, patients with persistently high sTREM-1 and decreased mHLA-DR presented with a significantly increased risk of infection (60%) compared with other patients (15.7%). This association remained significant in the multivariable model (subdistribution hazard ratio [95% CI], 4.65 [1.98-10.9]; p < 0.001).

CONCLUSIONS: In addition to its prognostic interest on mortality, sTREM-1, when combined with mHLA-DR, may help to better identify immunosuppressed patients at risk of nosocomial infections.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Venet M, Bidar F, Derive M, et al. Persistently Elevated Soluble Triggering Receptor Expressed on Myeloid Cells 1 and Decreased Monocyte Human Leucocyte Antigen DR Expression Are Associated With Nosocomial Infections in Septic Shock Patients. Crit Care Explor. 2023. PMID: 36861044. doi:10.1097/CCE.0000000000000869

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。